{"url_path":"/sec/fbiop/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 **    **Results of Operations and Financial Condition****.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1429260/0001104659-26-061208-index.html","accession_number":"0001104659-26-061208","cik":"0001429260","ticker":"FBIO","issuer_name":"Fortress Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1429260/0001104659-26-061208-index.html","primary_entity_key":"0001429260","primary_entity_name":"Fortress Biotech, Inc."},"word_count":132,"has_tables":true,"body_markdown":"**Item 2.02.**    **Results of Operations and Financial Condition****.**\n\n​\n\nOn May 14, 2026, Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the quarter ended March 31, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report.\n\n \n\nThe information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.\n\n​"}